Past 24 hours · live evidence
Evidence strength: weakWall Street rating · Buy
Analyst rating consensus
- Wall Street rating · BuyAnalyst rating consensus
- Beat market 20d +11%
Analyst rating consensus
No abnormal moves
No price data
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Valuation data from Financial Modeling Prep · TTM basis · Not investment advice
Wall Street consensus comes from FMP sell-side ratings and target prices · For reference only
Earnings dates and EPS data come from FMP and may shift near the filing date.